ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.27%. A quarter ago, it was expected that this company would post a loss of $0.40 per share when it actually produced earnings of $1.10, delivering a surprise of 375%. Over the last four quarters, the company has ...

S S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other juris ...

财务状况 - CRISPR Therapeutics在2024年第一季度的现金、现金等价物和可市场证券为21.08亿美元，较2023年底的16.957亿美元增加[19] - CRISPR Therapeutics AG总收入为504,000美元，较去年同期减少99.5%[38] - 现金及现金等价物为707,427,000美元，较上一季度增加81.6%[38] 研发进展 - CASGEVY™已在美国、英国、欧盟、沙特阿拉伯和巴林获得批准，用于治疗镰状细胞病和依赖输血的β地中海贫血[2] - CRISPR Therapeutics正在进行CTX112™和CTX131™的临床试验，分别针对CD19和CD70，跨多个适应症[6] - CTX310™和CTX320™是CRISPR Therapeutics的两个在进行中的临床试验，分别针对ANGPTL3和Lp(a)，与心血管疾病相关[10] - CTX211™是CRISPR Therapeutics用于治疗1型糖尿病的干细胞衍生治疗方案，目前正在进行I期临床试验[15] - CRISPR Therapeutics与Vertex合作开发CASGEVY™，Vertex负责全球开发、制造和商业化，与CRISPR Therapeutics分享成本和利润[25] - CTX112是CRISPR Therapeutics的下一代全基因组CAR T产品候选药物，针对CD19，正在进行临床试验[26] - CTX131是CRISPR Therapeutics的下一代全基因组CAR T产品候选药物，针对CD70，正在进行临床试验[27] 费用情况 - 研发费用为2024年第一季度的7620万美元，较2023年同期的9990万美元减少[20] - 研发支出为76,172,000美元，较去年同期减少23.8%[38] 盈亏情况 - CRISPR Therapeutics的净亏损为2024年第一季度的1.166亿美元，较2023年同期的5.31亿美元增加[23] - 总净亏损为116,591,000美元，较去年同期增加119.7%[38]

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so. These downturns, however, provide opportunities for investors to buy stocks at lower prices. The case is the same for which biotech stocks to buy in a down market. Knowing when to buy a stock during market turmoil can be the difference betwe ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this company have returned -18.5% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has lost 10.7% over this period. Now the key question is: Where could the stock b ...

janiecbros As investors search for disruptive companies within the biotech sector, it is helpful to consider disruptive technologies that necessarily precede them. Specifically, the revolutionary CRISPR/Cas9 gene-editing platform has recently made headlines with FDA approval of a revolutionary drug named Casgevy. This therapy, pioneered by CRISPR Therapeutics (NASDAQ: CRSP), amazingly recognizes the correct segment of DNA to edit by using a piece of RNA as a guide. The Cas9 protein then cuts the patient's D ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $53.91, indicating a +0.34% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%. Heading into today, shares of the company had lost 21.17% over the past month, lagging the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15% in that time. Analysts and investors alike will be keeping a close eye on the ...

CRISPR Therapeutics AG (CRSP) closed at $55.02 in the latest trading session, marking a -0.05% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.87%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 1.11%. Coming into today, shares of the company had lost 23.13% in the past month. In that same time, the Medical sector lost 6.67%, while the S&P 500 lost 3.97%. Market participants will be closely following the financial results of CRISPR Therapeutics A ...

股价表现 - Crispr Therapeutics AG (NASDAQ:CRSP) 股价在2月22日达到两年多来的高点后，现在已经下跌了2.8%，目前为每股56.35美元[1] - 过去一个月，CRSP股价下跌了20.8%，今年迄今为止的亏损率为9.6%[1] 技术指标 - Crispr Therapeutics 股票的14天相对强度指数（RSI）为18.2，处于“超卖”区域，通常表明会有短期反弹[3] - Crispr Therapeutics 股票的短期利空因子占流通股比例的17.6%，需要8天的交易量才能全部平仓[3] 波动性评估 - Crispr Therapeutics 股票的波动性评分（SVS）为86，表明该股票在过去12个月中超过了期权交易者的波动性预期，对于买方来说是一个好消息[4]